Brief: Nanobiotix SA Announces First Data From Completed Dose Escalation Part Of A Phase 1 Study Of NBTXR3 As A 2L+ Therapy For Locally Advanced NSCLC
27/03/2025 20:45
March 27 (Reuters) - Nanobiotix SA NANOB.PA: NANOBIOTIX SA: ANNOUNCES FIRST DATA FROM COMPLETED DOSE ESCALATION PART OF A PHASE 1 STUDY OF NBTXR3 AS A 2L+ THERAPY FOR LOCALLY ADVANCED NSCLC NANOBIOTIX SA: DATA SHOW FAVORABLE SAFETY AND CONFIRM INJECTION FEASIBILITY IN 12 PATIENTS WITH LOCALLY ADVANCED NSCLC AMENABLE TO RE-IRRADIATION NANOBIOTIX SA: PRELIMINARY REVIEW OF SURVIVAL DATA SHOWED 12-MONTH LPFS OF 64% AND 12-MONTH OS OF 83% IN PHASE 1 STUDY EVALUATING NBTXR3 Source text: ID:nGNX9kw8Gy Further company coverage: NANOB.PA ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Nanobiotix SA
See all newsBrief: Nanobiotix S.A. H1 Net Income EUR -34.3 Million
France's Nanobiotix H1 net loss widens on lower revenue, absence of 2025 one-off gain
Brief: Nanobiotix Reports Encouraging Full Phase 1 Results For Lung Cancer Drug JNJ-1900
Brief: Nanobiotix Q1 Cash And Cash Equivalents Of €42.1 Mln
Brief: NANOBIOTIX Announces Closing Of Global Offering